Superior to chemotherapy in delaying disease progression1*†
Adapted from TALZENNA SmPC. N Engl J Med 2018, 2 and data on file.337% of TALZENNA patients and 20% of chemotherapy patients did not have disease progression or death at 1 year, as determined by independent review2Consistent PFS results were observed across prespecified subgroups defined by study stratification factors1-3*‡§Adapted from TALZENNA SmPC.PFS significantly improved vs chemotherapy in patients with TNBC, HR+ disease, and history of CNS metastases4,5*§
- Median PFS of 8.6 months with TALZENNA – significantly longer than 5.6 months with chemotherapy1
Adapted from Rugo et al. JNCI Cancer Spectr. 2020.5
- All predefined subgroups below showed a PFS benefit in favor of TALZENNA
ABC=advanced breast cancer; BRCA=breast cancer susceptibility gene; Cl=confidence interval; CNS=central nervous system; DoR=duration of response; gBRCA=germline breast cancer susceptibility gene; GHS=global health status; HER2-=human epidermal growth factor receptor 2 negative; HR=hazard ratio; HR+=hormone receptor-positive; ITT=intent-to-treat; LA/mBC=locally advanced/metastatic breast cancer; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; QoL=quality of life; RECIST=Response Evaluation Criteria in Solid Tumors; TNBC=triple-negative breast cancer; TTR=time to response.PFS was determined by blinded independent central review (BICR), according to RECIST v1.1. Capecitabine, eribulin, gemcitabine, or vinorelbine.Study stratification factors include hormone receptor-expression status, BRCA mutation type, visceral/nonvisceral metastases, and with/without a history of CNS metastasis. Depicts subgroup analyses from the overall EMBRACA study population. Small patient numbers can be a limitation of subgroup analyses. Explore more Secondary endpoints
References:TALZENNA Summary of Product Characteristics. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753-763.Data on file. Pfizer Inc., New York, NY.Eiermann W, Rugo HS, Diab S, et al. Analysis of germline BRCA1/2 mutated (gBRCAm) hormone receptor-positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Poster presented at: Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2018; Chicago, IL. Poster 1070.Rugo HS, Ettl J, Hurvitz SA, et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. JNCI Cancer Spectr. 2020;4(1):1-12.
Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: ﬁnal overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526-1535.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of full SmPC for how to report adverse reactions.
Legal Category: S1A
Further information is available upon request
PP-TAL-IRL-0071 September 2023